4.6 Article

Familial hypercholesterolaemia: a study protocol for identification and investigation of potential causes and markers of subclinical coronary artery disease in the Faroe Islands

Journal

BMJ OPEN
Volume 12, Issue 4, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2021-050857

Keywords

Cardiac Epidemiology; Ischaemic heart disease; Echocardiography; Lipid disorders

Funding

  1. Research Council Faroe Islands [0334]
  2. National Hospital of the Faroe Islands
  3. Amgen

Ask authors/readers for more resources

This study aims to assess the prevalence, genetic and clinical characteristics, and potential causes of familial hypercholesterolaemia (FH) in the Faroe Islands. The research methods include estimating the prevalence of FH using a nationwide laboratory database, inviting eligible subjects for detailed evaluation, collecting samples for genetic testing and storage, and conducting cardiovascular examinations. The project has been approved by the ethical committee and data protection agency, and is expected to provide important information that will be published in international peer-reviewed journals.
Introduction Familial hypercholesterolaemia (FH) is the most common monogenic autosomal dominant genetic disorder and is associated with a high risk of premature atherosclerotic cardiovascular disease. The prevalence of FH has been reported to be particularly high in certain founder populations. The population of the Faroe Islands is a founder population, but the prevalence of FH has never been investigated here. We aim to assess the prevalence of FH and to describe the genetic and clinical characteristics and potential causes of FH in the Faroe Islands. Furthermore, we aim to investigate whether indicators of subclinical coronary artery disease are associated with FH. Methods and analysis The prevalence of FH will be estimated based on an electronic nationwide laboratory database that includes all measurements of plasma lipid levels in the Faroe Islands since 2006. Subsequently, we will identify and invite subjects aged between 18 and 75 years registered with a plasma low-density lipoprotein cholesterol above 6.7 mmol/L for diagnostic evaluation. Eligible FH cases will be matched to controls on age and sex. We aim to include 120 FH cases and 120 controls. Detailed information will be collected using questionnaires and interviews, and a physical examination will be undertaken. An adipose tissue biopsy and blood samples for genetic testing, detailed lipid analyses and samples for storage in a biobank for future research will be collected. Furthermore, FH cases and controls will be invited to have a transthoracic echocardiography and a cardiac CT performed. Ethics and dissemination The project has been approved by the Ethical Committee and the Data Protection Agency of the Faroe Islands. The project is expected to provide important information, which will be published in international peer-reviewed journals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available